Botulinum toxin typeA for the treatment of lower urinary tract disorders

Teruhiko Yokoyama, Michael B. Chancellor, Keiji Oguma, Yumiko Yamamoto, Tomonori Suzuki, Hiromi Kumon, Atsushi Nagai

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Many papers report the clinical success of botulinum toxinA as a method of management of various bladder dysfunctions. The rationale was that botulinum toxinA was able to block the presynaptic release of acetylcholine from the parasympathetic efferent nerve. The efficacy might result not only from an inhibitory effect on detrusor muscle, but also some effects might be mediated by altering the afferent nerve input. This systematic literature review discusses the efficacy and safety of botulinum toxinA therapy for idiopathic detrusor overactivity, neurogenic detrusor overactivity, interstitial cystitis/painful bladder syndrome and benign prostatic hyperplasia. The information was gathered from a PubMed literature research for abstracts from recent urological meetings. Injection of botulinum toxinA appears to have a positive therapeutic effect in multiple urological conditions, such as refractory idiopathic detrusor overactivity, neurogenic detrusor overactivity, interstitial cystitis/painful bladder syndrome and benign prostatic hyperplasia. Because the United States Food and Drug Administration has approved botulinum toxinA (Botox) for injection for the treatment of urinary incontinence as a result of neurogenic detrusor overactivity (e.g. spinal cord injury, multiple sclerosis) in adults who have an inadequate response to or are intolerant of an ant cholinergic medication, the use of botulinum toxinA will spread and be a more familiar therapy in the urological arena. However, further robust evidence should be awaited. We will discuss the current use of this agent within the urological field.

Original languageEnglish
Pages (from-to)202-215
Number of pages14
JournalInternational Journal of Urology
Volume19
Issue number3
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Interstitial Cystitis
Botulinum Toxins
Urinary Tract
Prostatic Hyperplasia
Urological Agents
Injections
Ants
Urinary Incontinence
Therapeutic Uses
United States Food and Drug Administration
Therapeutics
Spinal Cord Injuries
PubMed
Cholinergic Agents
Acetylcholine
Multiple Sclerosis
Urinary Bladder
Safety
Muscles
Research

Keywords

  • Bladder
  • Botulinum toxin typeA
  • Detrusor overactivity
  • Idiopathic
  • Neurogenic
  • Prostate
  • Urethra

ASJC Scopus subject areas

  • Urology
  • Medicine(all)

Cite this

Botulinum toxin typeA for the treatment of lower urinary tract disorders. / Yokoyama, Teruhiko; Chancellor, Michael B.; Oguma, Keiji; Yamamoto, Yumiko; Suzuki, Tomonori; Kumon, Hiromi; Nagai, Atsushi.

In: International Journal of Urology, Vol. 19, No. 3, 03.2012, p. 202-215.

Research output: Contribution to journalArticle

Yokoyama, T, Chancellor, MB, Oguma, K, Yamamoto, Y, Suzuki, T, Kumon, H & Nagai, A 2012, 'Botulinum toxin typeA for the treatment of lower urinary tract disorders', International Journal of Urology, vol. 19, no. 3, pp. 202-215. https://doi.org/10.1111/j.1442-2042.2011.02946.x
Yokoyama, Teruhiko ; Chancellor, Michael B. ; Oguma, Keiji ; Yamamoto, Yumiko ; Suzuki, Tomonori ; Kumon, Hiromi ; Nagai, Atsushi. / Botulinum toxin typeA for the treatment of lower urinary tract disorders. In: International Journal of Urology. 2012 ; Vol. 19, No. 3. pp. 202-215.
@article{e0f7eb17e8354c178704ddc71fa41fe3,
title = "Botulinum toxin typeA for the treatment of lower urinary tract disorders",
abstract = "Many papers report the clinical success of botulinum toxinA as a method of management of various bladder dysfunctions. The rationale was that botulinum toxinA was able to block the presynaptic release of acetylcholine from the parasympathetic efferent nerve. The efficacy might result not only from an inhibitory effect on detrusor muscle, but also some effects might be mediated by altering the afferent nerve input. This systematic literature review discusses the efficacy and safety of botulinum toxinA therapy for idiopathic detrusor overactivity, neurogenic detrusor overactivity, interstitial cystitis/painful bladder syndrome and benign prostatic hyperplasia. The information was gathered from a PubMed literature research for abstracts from recent urological meetings. Injection of botulinum toxinA appears to have a positive therapeutic effect in multiple urological conditions, such as refractory idiopathic detrusor overactivity, neurogenic detrusor overactivity, interstitial cystitis/painful bladder syndrome and benign prostatic hyperplasia. Because the United States Food and Drug Administration has approved botulinum toxinA (Botox) for injection for the treatment of urinary incontinence as a result of neurogenic detrusor overactivity (e.g. spinal cord injury, multiple sclerosis) in adults who have an inadequate response to or are intolerant of an ant cholinergic medication, the use of botulinum toxinA will spread and be a more familiar therapy in the urological arena. However, further robust evidence should be awaited. We will discuss the current use of this agent within the urological field.",
keywords = "Bladder, Botulinum toxin typeA, Detrusor overactivity, Idiopathic, Neurogenic, Prostate, Urethra",
author = "Teruhiko Yokoyama and Chancellor, {Michael B.} and Keiji Oguma and Yumiko Yamamoto and Tomonori Suzuki and Hiromi Kumon and Atsushi Nagai",
year = "2012",
month = "3",
doi = "10.1111/j.1442-2042.2011.02946.x",
language = "English",
volume = "19",
pages = "202--215",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Botulinum toxin typeA for the treatment of lower urinary tract disorders

AU - Yokoyama, Teruhiko

AU - Chancellor, Michael B.

AU - Oguma, Keiji

AU - Yamamoto, Yumiko

AU - Suzuki, Tomonori

AU - Kumon, Hiromi

AU - Nagai, Atsushi

PY - 2012/3

Y1 - 2012/3

N2 - Many papers report the clinical success of botulinum toxinA as a method of management of various bladder dysfunctions. The rationale was that botulinum toxinA was able to block the presynaptic release of acetylcholine from the parasympathetic efferent nerve. The efficacy might result not only from an inhibitory effect on detrusor muscle, but also some effects might be mediated by altering the afferent nerve input. This systematic literature review discusses the efficacy and safety of botulinum toxinA therapy for idiopathic detrusor overactivity, neurogenic detrusor overactivity, interstitial cystitis/painful bladder syndrome and benign prostatic hyperplasia. The information was gathered from a PubMed literature research for abstracts from recent urological meetings. Injection of botulinum toxinA appears to have a positive therapeutic effect in multiple urological conditions, such as refractory idiopathic detrusor overactivity, neurogenic detrusor overactivity, interstitial cystitis/painful bladder syndrome and benign prostatic hyperplasia. Because the United States Food and Drug Administration has approved botulinum toxinA (Botox) for injection for the treatment of urinary incontinence as a result of neurogenic detrusor overactivity (e.g. spinal cord injury, multiple sclerosis) in adults who have an inadequate response to or are intolerant of an ant cholinergic medication, the use of botulinum toxinA will spread and be a more familiar therapy in the urological arena. However, further robust evidence should be awaited. We will discuss the current use of this agent within the urological field.

AB - Many papers report the clinical success of botulinum toxinA as a method of management of various bladder dysfunctions. The rationale was that botulinum toxinA was able to block the presynaptic release of acetylcholine from the parasympathetic efferent nerve. The efficacy might result not only from an inhibitory effect on detrusor muscle, but also some effects might be mediated by altering the afferent nerve input. This systematic literature review discusses the efficacy and safety of botulinum toxinA therapy for idiopathic detrusor overactivity, neurogenic detrusor overactivity, interstitial cystitis/painful bladder syndrome and benign prostatic hyperplasia. The information was gathered from a PubMed literature research for abstracts from recent urological meetings. Injection of botulinum toxinA appears to have a positive therapeutic effect in multiple urological conditions, such as refractory idiopathic detrusor overactivity, neurogenic detrusor overactivity, interstitial cystitis/painful bladder syndrome and benign prostatic hyperplasia. Because the United States Food and Drug Administration has approved botulinum toxinA (Botox) for injection for the treatment of urinary incontinence as a result of neurogenic detrusor overactivity (e.g. spinal cord injury, multiple sclerosis) in adults who have an inadequate response to or are intolerant of an ant cholinergic medication, the use of botulinum toxinA will spread and be a more familiar therapy in the urological arena. However, further robust evidence should be awaited. We will discuss the current use of this agent within the urological field.

KW - Bladder

KW - Botulinum toxin typeA

KW - Detrusor overactivity

KW - Idiopathic

KW - Neurogenic

KW - Prostate

KW - Urethra

UR - http://www.scopus.com/inward/record.url?scp=84857358284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857358284&partnerID=8YFLogxK

U2 - 10.1111/j.1442-2042.2011.02946.x

DO - 10.1111/j.1442-2042.2011.02946.x

M3 - Article

C2 - 22220916

AN - SCOPUS:84857358284

VL - 19

SP - 202

EP - 215

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 3

ER -